Gene Therapy

Biotech By Adam Feuerstein

Bluebird suspends studies of sickle cell gene therapy following cancer diagnoses in two more treated patients

Biotech By Adam Feuerstein

Sarepta gene therapy for Duchenne muscular dystrophy stumbles with failed study outcome

Biotech By Kate Sheridan

Startup Spotlight: Encoded eyes a gene therapy for Dravet syndrome

Biotech By Adam Feuerstein

New rare disease gene therapy startup recruits former Sarepta executive as CEO

Health By Elizabeth Cooney

Recapping ASCO 2020, talking cancer therapy combinations, and looking to the future

Biotech By Matthew Herper

Pfizer says efficacy of its Duchenne gene therapy outweighs side effects

Biotech By Kate Sheridan

This biotech just bought three failed drugs. Here’s why

In the Lab By Rebecca Robbins

Gene therapy pioneer says the field is behind — and that delivery technology is ‘embarrassing’

Pharmalot By Ed Silverman

Novartis unit says FDA wasn’t told of data manipulation sooner because it was ‘highly complex’

Biotech By Jonathan Saltzman — Boston Globe

The world’s most expensive medicine could save toddlers’ lives. But getting it is complicated

Biotech By Adam Feuerstein

Bluebird’s gene therapy for a rare blood disease will cost $1.8 million. Cue the pricing debate

Biotech By Damian Garde

Europe approves first gene therapy to treat rare blood disease

Biotech By Adam Feuerstein and Matthew Herper

Biomarin to seek approval for hemophilia gene therapy, but durability questions persist

Biotech By Jonathan Saltzman — Boston Globe

Novartis CEO coy about pricing its gene therapy for spinal muscular atrophy

Biotech By Adam Feuerstein

Tocagen continues a brain cancer gene therapy clinical trial. Investors fear the worst

Biotech By Adam Feuerstein

BioMarin’s hemophilia gene therapy faces a crucial durability test. Here are 9 things to know

Biotech By Adam Feuerstein

With positive early results, Sarepta appears to have a second gene therapy with potential

Biotech By Matthew Herper

Solid Biosciences to soldier on as initial muscular dystrophy gene therapy results disappoint

Biotech By Adam Feuerstein

With new data, a biotech tries to relieve doubts about the durability of its gene therapy for Fabry disease

Adam's Take By Adam Feuerstein

Misfortune strikes a Bluebird patient, highlighting the safety risks involved with gene therapy

Biotech By Adam Feuerstein

Amicus Therapeutics acquires portfolio of gene therapies targeting neurologic disorders

Adam's Take By Adam Feuerstein

A gene therapy for overactive bladder? A waste of time and money that trivializes a lifesaving technology

Biotech By Ike Swetlitz

FDA plans to speed path to approval for some gene therapies, starting with hemophilia

Pharmalot By Ed Silverman

Pharmalittle: Insulin study causes a big flap; Glaxo gets a reprieve thanks to a Novartis setback

Biotech By Adam Feuerstein

Most Read

‘That’s $425,000 right there’ — the anxious launch of a gene therapy with a record sticker price

In a shocking decision, FDA rejects BioMarin’s gene therapy for hemophilia

At $2.1 million, newly approved Novartis gene therapy will be world’s most expensive drug

Should employers take a chance on little-known Embarc to pay for gene therapy?

30 years is too long to wait for new medicines. There are ways to speed up drug development

How much would you pay for the miracle of gene therapy?

There’s a possible cure for ‘bubble boy’ disease. It will cost $665,000

New therapy offers gene fix for ‘bubble boy’ disease

All Coverage

Bluebird suspends studies of sickle cell gene therapy following cancer diagnoses in two more treated patients

Sarepta gene therapy for Duchenne muscular dystrophy stumbles with failed study outcome

Startup Spotlight: Encoded eyes a gene therapy for Dravet syndrome

New rare disease gene therapy startup recruits former Sarepta executive as CEO

Recapping ASCO 2020, talking cancer therapy combinations, and looking to the future

Pfizer says efficacy of its Duchenne gene therapy outweighs side effects

This biotech just bought three failed drugs. Here’s why

Gene therapy pioneer says the field is behind — and that delivery technology is ‘embarrassing’

Novartis unit says FDA wasn’t told of data manipulation sooner because it was ‘highly complex’

The world’s most expensive medicine could save toddlers’ lives. But getting it is complicated

Bluebird’s gene therapy for a rare blood disease will cost $1.8 million. Cue the pricing debate

Europe approves first gene therapy to treat rare blood disease

Biomarin to seek approval for hemophilia gene therapy, but durability questions persist

Novartis CEO coy about pricing its gene therapy for spinal muscular atrophy

Tocagen continues a brain cancer gene therapy clinical trial. Investors fear the worst

BioMarin’s hemophilia gene therapy faces a crucial durability test. Here are 9 things to know

With positive early results, Sarepta appears to have a second gene therapy with potential

Solid Biosciences to soldier on as initial muscular dystrophy gene therapy results disappoint

With new data, a biotech tries to relieve doubts about the durability of its gene therapy for Fabry disease

Misfortune strikes a Bluebird patient, highlighting the safety risks involved with gene therapy

Amicus Therapeutics acquires portfolio of gene therapies targeting neurologic disorders

A gene therapy for overactive bladder? A waste of time and money that trivializes a lifesaving technology

FDA plans to speed path to approval for some gene therapies, starting with hemophilia

Pharmalittle: Insulin study causes a big flap; Glaxo gets a reprieve thanks to a Novartis setback

New paper raises safety concerns about neuro gene therapy, stocks slide